Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-11

AUTHORS

Hyung-Jun Kim, Jong Sik Lee, Nakwon Kwak, Jaeyoung Cho, Chang-Hoon Lee, Sung Koo Han, Jae-Joon Yim

ABSTRACT

BackgroundA three-drug regimen (macrolide, ethambutol, and rifampicin) is recommended for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). Although macrolide has proven efficacy, the role of ethambutol and rifampicin in patients without acquired immune deficiency syndrome is not proven with clinical studies. We aimed to clarify the roles of ethambutol and rifampicin in the treatment of MAC-PD.MethodsPatients treated for MAC-PD between March 1st, 2009 and October 31st, 2018 were reviewed retrospectively. Rates of culture conversion, microbiological cure, treatment failure, and recurrence were compared according to the maintenance (≥6 months) of ethambutol or rifampicin with macrolide.ResultsAmong the 237 patients, 122 (51.5%) maintained ethambutol and rifampicin with macrolide, 58 (24.5%) maintained ethambutol and macrolide, 32 (13.5%) maintained rifampicin and macrolide, and 25 (10.6%) maintained macrolide only. Culture conversion was reached for 190/237 (80.2%) patients and microbiological cure was achieved for 129/177 (72.9%) who completed the treatment. Treatment failure despite ≥12 months of treatment was observed in 66/204 (32.4%), and recurrence was identified in 16/129 (12.4%) who achieved microbiological cure. Compared with maintenance of macrolide only, maintenance of ethambutol, rifampicin or both with macrolide were associated with higher odds of culture conversion [odds ratio (OR), 95% confidence interval (CI): 18.06, 3.67–88.92; 15.82, 2.38–105.33; and 17.12, 3.93–74.60, respectively]. Higher odds of microbiological cure were associated with maintenance of both ethambutol and rifampicin with macrolide (OR, 95% CI: 5.74, 1.54–21.42) and macrolide and ethambutol (OR, 95% CI: 5.12, 1.72–15.24) but not macrolide and rifampicin. Maintenance of both ethambutol and rifampicin with macrolide was associated with lower odds of treatment failure (OR, 95% CI: 0.09, 0.01–0.53) compared with macrolide only, while maintenance of one of these with macrolide was not. Maintenance of both ethambutol and rifampicin or one of these with macrolide did not decrease the probability of recurrence when compared with macrolide only.ConclusionsMaintenance (≥6 months) of ethambutol and rifampicin with macrolide was associated with the most favorable treatment outcomes among patients with MAC-PD. Given the association between ongoing ethambutol use and microbiological cure, clinicians should maintain ethambutol unless definite adverse events develop. More... »

PAGES

212

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12890-019-0982-8

DOI

http://dx.doi.org/10.1186/s12890-019-0982-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1122493703

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31711459


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antitubercular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antitubercular Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethambutol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycobacterium avium Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycobacterium avium-intracellulare Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiography, Thoracic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rifampin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Hyung-Jun", 
        "id": "sg:person.0764606415.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764606415.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary Medicine, Department of Internal Medicine, Mediplex Sejong Hospital, 20 Gyeyangmunhwa-ro Gyeyang-gu, 21080, Incheon, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Pulmonary Medicine, Department of Internal Medicine, Mediplex Sejong Hospital, 20 Gyeyangmunhwa-ro Gyeyang-gu, 21080, Incheon, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jong Sik", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kwak", 
        "givenName": "Nakwon", 
        "id": "sg:person.0711211055.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711211055.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cho", 
        "givenName": "Jaeyoung", 
        "id": "sg:person.01012515515.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012515515.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.412484.f", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Chang-Hoon", 
        "id": "sg:person.0743464132.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464132.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "Sung Koo", 
        "id": "sg:person.01237102766.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237102766.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yim", 
        "givenName": "Jae-Joon", 
        "id": "sg:person.01162551442.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162551442.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2334-13-558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000020320", 
          "https://doi.org/10.1186/1471-2334-13-558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02014241", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017876604", 
          "https://doi.org/10.1007/bf02014241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12890-016-0349-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041684646", 
          "https://doi.org/10.1186/s12890-016-0349-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-11-11", 
    "datePublishedReg": "2019-11-11", 
    "description": "BackgroundA three-drug regimen (macrolide, ethambutol, and rifampicin) is recommended for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). Although macrolide has proven efficacy, the role of ethambutol and rifampicin in patients without acquired immune deficiency syndrome is not proven with clinical studies. We aimed to clarify the roles of ethambutol and rifampicin in the treatment of MAC-PD.MethodsPatients treated for MAC-PD between March 1st, 2009 and October 31st, 2018 were reviewed retrospectively. Rates of culture conversion, microbiological cure, treatment failure, and recurrence were compared according to the maintenance (\u22656\u2009months) of ethambutol or rifampicin with macrolide.ResultsAmong the 237 patients, 122 (51.5%) maintained ethambutol and rifampicin with macrolide, 58 (24.5%) maintained ethambutol and macrolide, 32 (13.5%) maintained rifampicin and macrolide, and 25 (10.6%) maintained macrolide only. Culture conversion was reached for 190/237 (80.2%) patients and microbiological cure was achieved for 129/177 (72.9%) who completed the treatment. Treatment failure despite \u226512\u2009months of treatment was observed in 66/204 (32.4%), and recurrence was identified in 16/129 (12.4%) who achieved microbiological cure. Compared with maintenance of macrolide only, maintenance of ethambutol, rifampicin or both with macrolide were associated with higher odds of culture conversion [odds ratio (OR), 95% confidence interval (CI): 18.06, 3.67\u201388.92; 15.82, 2.38\u2013105.33; and 17.12, 3.93\u201374.60, respectively]. Higher odds of microbiological cure were associated with maintenance of both ethambutol and rifampicin with macrolide (OR, 95% CI: 5.74, 1.54\u201321.42) and macrolide and ethambutol (OR, 95% CI: 5.12, 1.72\u201315.24) but not macrolide and rifampicin. Maintenance of both ethambutol and rifampicin with macrolide was associated with lower odds of treatment failure (OR, 95% CI: 0.09, 0.01\u20130.53) compared with macrolide only, while maintenance of one of these with macrolide was not. Maintenance of both ethambutol and rifampicin or one of these with macrolide did not decrease the probability of recurrence when compared with macrolide only.ConclusionsMaintenance (\u22656\u2009months) of ethambutol and rifampicin with macrolide was associated with the most favorable treatment outcomes among patients with MAC-PD. Given the association between ongoing ethambutol use and microbiological cure, clinicians should maintain ethambutol unless definite adverse events develop.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12890-019-0982-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024955", 
        "issn": [
          "1471-2466"
        ], 
        "name": "BMC Pulmonary Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "Mycobacterium avium complex pulmonary disease", 
      "microbiological cure", 
      "complex pulmonary disease", 
      "MAC-PD", 
      "culture conversion", 
      "treatment failure", 
      "pulmonary disease", 
      "higher odds", 
      "three-drug regimen", 
      "definite adverse events", 
      "months of treatment", 
      "immune deficiency syndrome", 
      "favorable treatment outcomes", 
      "probability of recurrence", 
      "ethambutol use", 
      "adverse events", 
      "deficiency syndrome", 
      "treatment outcomes", 
      "clinical studies", 
      "lower odds", 
      "ethambutol", 
      "patients", 
      "recurrence", 
      "rifampicin", 
      "cure", 
      "treatment", 
      "odds", 
      "macrolides", 
      "disease", 
      "failure", 
      "MethodsPatients", 
      "regimen", 
      "ResultsAmong", 
      "syndrome", 
      "clinicians", 
      "months", 
      "efficacy", 
      "role", 
      "outcomes", 
      "maintenance", 
      "association", 
      "study", 
      "rate", 
      "events", 
      "use", 
      "conversion", 
      "probability"
    ], 
    "name": "Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease", 
    "pagination": "212", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1122493703"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12890-019-0982-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31711459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12890-019-0982-8", 
      "https://app.dimensions.ai/details/publication/pub.1122493703"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_826.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12890-019-0982-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12890-019-0982-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12890-019-0982-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12890-019-0982-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12890-019-0982-8'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      21 PREDICATES      95 URIs      84 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12890-019-0982-8 schema:about N00bf5eacb7b44887b9d68a2a782e7a24
2 N14725b58d90c4466bbaa06d32cc5e882
3 N1ee114623996496887dafd855302ae7e
4 N3a507f06d5ea46a9a90553aca759fa64
5 N47466426c249451d896474b71345c6ae
6 N5681cf39c69e42aa9b13fe08d2d8383c
7 N5f705e2864ae4fd0b0b16b27028e7b95
8 N65e219f30db044619b8ca245bdec1bee
9 N92a4f42ec29e4c4c971814a79eee843e
10 N92d349c02d994d528dfa14fe2257166f
11 N9abb58e7f7ad4d7b8f8007add919e2b0
12 N9b9d667280d44cddb734de94abefd18d
13 Na337406deae84061b691ecdad648bbbc
14 Nae5420579d974cfdb112db252320f316
15 Nb5c0742fef344227931dd2e289dd6dc3
16 Nbd887e07328746c98a49c5be4dbb1d00
17 Nc4cac3bbe6e146498a7ab7a31efd94ad
18 Nc4dd7e90936f4e09af445ba4c45c58c1
19 Ncb504005d66446c780980b87582409d1
20 Nd67530b9c9614b339be5ab5dac214722
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N49ef09b6f86f45f39a3b0f65ba7a97ca
24 schema:citation sg:pub.10.1007/bf02014241
25 sg:pub.10.1186/1471-2334-13-558
26 sg:pub.10.1186/s12890-016-0349-3
27 schema:datePublished 2019-11-11
28 schema:datePublishedReg 2019-11-11
29 schema:description BackgroundA three-drug regimen (macrolide, ethambutol, and rifampicin) is recommended for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). Although macrolide has proven efficacy, the role of ethambutol and rifampicin in patients without acquired immune deficiency syndrome is not proven with clinical studies. We aimed to clarify the roles of ethambutol and rifampicin in the treatment of MAC-PD.MethodsPatients treated for MAC-PD between March 1st, 2009 and October 31st, 2018 were reviewed retrospectively. Rates of culture conversion, microbiological cure, treatment failure, and recurrence were compared according to the maintenance (≥6 months) of ethambutol or rifampicin with macrolide.ResultsAmong the 237 patients, 122 (51.5%) maintained ethambutol and rifampicin with macrolide, 58 (24.5%) maintained ethambutol and macrolide, 32 (13.5%) maintained rifampicin and macrolide, and 25 (10.6%) maintained macrolide only. Culture conversion was reached for 190/237 (80.2%) patients and microbiological cure was achieved for 129/177 (72.9%) who completed the treatment. Treatment failure despite ≥12 months of treatment was observed in 66/204 (32.4%), and recurrence was identified in 16/129 (12.4%) who achieved microbiological cure. Compared with maintenance of macrolide only, maintenance of ethambutol, rifampicin or both with macrolide were associated with higher odds of culture conversion [odds ratio (OR), 95% confidence interval (CI): 18.06, 3.67–88.92; 15.82, 2.38–105.33; and 17.12, 3.93–74.60, respectively]. Higher odds of microbiological cure were associated with maintenance of both ethambutol and rifampicin with macrolide (OR, 95% CI: 5.74, 1.54–21.42) and macrolide and ethambutol (OR, 95% CI: 5.12, 1.72–15.24) but not macrolide and rifampicin. Maintenance of both ethambutol and rifampicin with macrolide was associated with lower odds of treatment failure (OR, 95% CI: 0.09, 0.01–0.53) compared with macrolide only, while maintenance of one of these with macrolide was not. Maintenance of both ethambutol and rifampicin or one of these with macrolide did not decrease the probability of recurrence when compared with macrolide only.ConclusionsMaintenance (≥6 months) of ethambutol and rifampicin with macrolide was associated with the most favorable treatment outcomes among patients with MAC-PD. Given the association between ongoing ethambutol use and microbiological cure, clinicians should maintain ethambutol unless definite adverse events develop.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf N215c42b2934e4c6194f7fcbc3533dab1
33 N946c7a98f1d7496f8859a1c202cde58e
34 sg:journal.1024955
35 schema:keywords MAC-PD
36 MethodsPatients
37 Mycobacterium avium complex pulmonary disease
38 ResultsAmong
39 adverse events
40 association
41 clinical studies
42 clinicians
43 complex pulmonary disease
44 conversion
45 culture conversion
46 cure
47 deficiency syndrome
48 definite adverse events
49 disease
50 efficacy
51 ethambutol
52 ethambutol use
53 events
54 failure
55 favorable treatment outcomes
56 higher odds
57 immune deficiency syndrome
58 lower odds
59 macrolides
60 maintenance
61 microbiological cure
62 months
63 months of treatment
64 odds
65 outcomes
66 patients
67 probability
68 probability of recurrence
69 pulmonary disease
70 rate
71 recurrence
72 regimen
73 rifampicin
74 role
75 study
76 syndrome
77 three-drug regimen
78 treatment
79 treatment failure
80 treatment outcomes
81 use
82 schema:name Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease
83 schema:pagination 212
84 schema:productId N5af53e2dda7449d3b810171a17d47120
85 N5bc10fb4115247f5847d77a0a3628811
86 Ncef8dc5f44a24021a7070f197fea9dc1
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122493703
88 https://doi.org/10.1186/s12890-019-0982-8
89 schema:sdDatePublished 2022-09-02T16:03
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher N4e898bb58c8e469395c640f4691b97d0
92 schema:url https://doi.org/10.1186/s12890-019-0982-8
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N00bf5eacb7b44887b9d68a2a782e7a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Lung Diseases
98 rdf:type schema:DefinedTerm
99 N14725b58d90c4466bbaa06d32cc5e882 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Drug Therapy, Combination
101 rdf:type schema:DefinedTerm
102 N1ee114623996496887dafd855302ae7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Middle Aged
104 rdf:type schema:DefinedTerm
105 N215c42b2934e4c6194f7fcbc3533dab1 schema:issueNumber 1
106 rdf:type schema:PublicationIssue
107 N215dc31be5df4eb8b78d330436e35c5b rdf:first sg:person.01237102766.14
108 rdf:rest Ne9a66287588f4aa98a0bc3df414f8d38
109 N3a507f06d5ea46a9a90553aca759fa64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Ethambutol
111 rdf:type schema:DefinedTerm
112 N47466426c249451d896474b71345c6ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Aged
114 rdf:type schema:DefinedTerm
115 N49ef09b6f86f45f39a3b0f65ba7a97ca rdf:first sg:person.0764606415.21
116 rdf:rest Nc5fa0586366a47759bff589c419ab916
117 N4bc145d0890a46da9548a7863e940b73 rdf:first sg:person.01012515515.84
118 rdf:rest Ndc6136467e35485a8140871a8aa2f756
119 N4e898bb58c8e469395c640f4691b97d0 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N5681cf39c69e42aa9b13fe08d2d8383c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Female
123 rdf:type schema:DefinedTerm
124 N5af53e2dda7449d3b810171a17d47120 schema:name dimensions_id
125 schema:value pub.1122493703
126 rdf:type schema:PropertyValue
127 N5bc10fb4115247f5847d77a0a3628811 schema:name doi
128 schema:value 10.1186/s12890-019-0982-8
129 rdf:type schema:PropertyValue
130 N5f705e2864ae4fd0b0b16b27028e7b95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N65e219f30db044619b8ca245bdec1bee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Radiography, Thoracic
135 rdf:type schema:DefinedTerm
136 N92a4f42ec29e4c4c971814a79eee843e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Adult
138 rdf:type schema:DefinedTerm
139 N92d349c02d994d528dfa14fe2257166f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Retrospective Studies
141 rdf:type schema:DefinedTerm
142 N946c7a98f1d7496f8859a1c202cde58e schema:volumeNumber 19
143 rdf:type schema:PublicationVolume
144 N9abb58e7f7ad4d7b8f8007add919e2b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Treatment Outcome
146 rdf:type schema:DefinedTerm
147 N9b9d667280d44cddb734de94abefd18d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Rifampin
149 rdf:type schema:DefinedTerm
150 Na337406deae84061b691ecdad648bbbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Time Factors
152 rdf:type schema:DefinedTerm
153 Na57e7c1b937c40a381f973624342ff1e rdf:first sg:person.0711211055.17
154 rdf:rest N4bc145d0890a46da9548a7863e940b73
155 Nae5420579d974cfdb112db252320f316 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antibiotics, Antitubercular
157 rdf:type schema:DefinedTerm
158 Nb5c0742fef344227931dd2e289dd6dc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Mycobacterium avium-intracellulare Infection
160 rdf:type schema:DefinedTerm
161 Nbd887e07328746c98a49c5be4dbb1d00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Young Adult
163 rdf:type schema:DefinedTerm
164 Nc36f0c25cd4747eab683a25849f651bd schema:affiliation grid-institutes:None
165 schema:familyName Lee
166 schema:givenName Jong Sik
167 rdf:type schema:Person
168 Nc4cac3bbe6e146498a7ab7a31efd94ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Follow-Up Studies
170 rdf:type schema:DefinedTerm
171 Nc4dd7e90936f4e09af445ba4c45c58c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Male
173 rdf:type schema:DefinedTerm
174 Nc5fa0586366a47759bff589c419ab916 rdf:first Nc36f0c25cd4747eab683a25849f651bd
175 rdf:rest Na57e7c1b937c40a381f973624342ff1e
176 Ncb504005d66446c780980b87582409d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Antitubercular Agents
178 rdf:type schema:DefinedTerm
179 Ncef8dc5f44a24021a7070f197fea9dc1 schema:name pubmed_id
180 schema:value 31711459
181 rdf:type schema:PropertyValue
182 Nd67530b9c9614b339be5ab5dac214722 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Mycobacterium avium Complex
184 rdf:type schema:DefinedTerm
185 Ndc6136467e35485a8140871a8aa2f756 rdf:first sg:person.0743464132.81
186 rdf:rest N215dc31be5df4eb8b78d330436e35c5b
187 Ne9a66287588f4aa98a0bc3df414f8d38 rdf:first sg:person.01162551442.12
188 rdf:rest rdf:nil
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
193 schema:name Clinical Sciences
194 rdf:type schema:DefinedTerm
195 sg:journal.1024955 schema:issn 1471-2466
196 schema:name BMC Pulmonary Medicine
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01012515515.84 schema:affiliation grid-institutes:grid.31501.36
200 schema:familyName Cho
201 schema:givenName Jaeyoung
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012515515.84
203 rdf:type schema:Person
204 sg:person.01162551442.12 schema:affiliation grid-institutes:grid.31501.36
205 schema:familyName Yim
206 schema:givenName Jae-Joon
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162551442.12
208 rdf:type schema:Person
209 sg:person.01237102766.14 schema:affiliation grid-institutes:grid.31501.36
210 schema:familyName Han
211 schema:givenName Sung Koo
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237102766.14
213 rdf:type schema:Person
214 sg:person.0711211055.17 schema:affiliation grid-institutes:grid.31501.36
215 schema:familyName Kwak
216 schema:givenName Nakwon
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711211055.17
218 rdf:type schema:Person
219 sg:person.0743464132.81 schema:affiliation grid-institutes:grid.412484.f
220 schema:familyName Lee
221 schema:givenName Chang-Hoon
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464132.81
223 rdf:type schema:Person
224 sg:person.0764606415.21 schema:affiliation grid-institutes:grid.31501.36
225 schema:familyName Kim
226 schema:givenName Hyung-Jun
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764606415.21
228 rdf:type schema:Person
229 sg:pub.10.1007/bf02014241 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017876604
230 https://doi.org/10.1007/bf02014241
231 rdf:type schema:CreativeWork
232 sg:pub.10.1186/1471-2334-13-558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000020320
233 https://doi.org/10.1186/1471-2334-13-558
234 rdf:type schema:CreativeWork
235 sg:pub.10.1186/s12890-016-0349-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041684646
236 https://doi.org/10.1186/s12890-016-0349-3
237 rdf:type schema:CreativeWork
238 grid-institutes:None schema:alternateName Division of Pulmonary Medicine, Department of Internal Medicine, Mediplex Sejong Hospital, 20 Gyeyangmunhwa-ro Gyeyang-gu, 21080, Incheon, Republic of Korea
239 schema:name Division of Pulmonary Medicine, Department of Internal Medicine, Mediplex Sejong Hospital, 20 Gyeyangmunhwa-ro Gyeyang-gu, 21080, Incheon, Republic of Korea
240 rdf:type schema:Organization
241 grid-institutes:grid.31501.36 schema:alternateName Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea
242 schema:name Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea
243 rdf:type schema:Organization
244 grid-institutes:grid.412484.f schema:alternateName Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea
245 schema:name Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, 03080, Seoul, Republic of Korea
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...